EFSA to discuss health claims
This article was originally published in The Tan Sheet
Executive Summary
The European Food Safety Authority schedules a June 1 technical meeting to provide an update on its ongoing nutrition and health claim evaluation and an opportunity for industry stakeholders to engage with experts from the Scientific Panel on Dietetic Products, Nutrition and Allergies, which evaluates the claims submitted by EU member states. EFSA said the meeting in Parma, Italy, also will review the general conditions, scientific criteria and pertinent studies for claim substantiation. Europe's nutritional products industry likely will seek clarity from EFSA on the claims evaluation process at the meeting, given the prevalence of negative opinions issued thus far and the sentiment held by many in industry that the criteria for claims are too rigid (1"The Tan Sheet" March 1, 2010, In Brief)
You may also be interested in...
EFSA addresses topic-specific health claims
The European Food Safety Authority schedules a series of online consultations and public meetings on health claims in specific areas, beginning with a Dec. 2 meeting on the scientific substantiation needed for gut and immune function claims. The authority says a draft guidance on gut and immunity claims it will publish in October will be discussed, along with public comments, at the meeting in Amsterdam. Food industry scientists and other stakeholders can anticipate sessions on claims relating to weight management, oxidative damage, cardiovascular health and cognitive function planned for 2011 and 2012. EFSA seeks to engage with stakeholders to clarify expectations for claim substantiation (1"The Tan Sheet" April 26, 2010, In Brief)
EFSA rejects more health claims
The European Food Safety Authority gave most health claims in the second wave of evaluations unfavorable opinions "due to the poor quality of the information provided," EFSA says Feb. 25. The authority's Panel on Dietetic Products, Nutrition and Allergies cited insufficient information to identify substances and insufficient evidence that claimed effects benefit the body. Many of the 416 claims evaluated were not supported by human studies with reliable measures, EFSA said. The panel sent its opinions to the European Commission and EU members, which will decide whether to authorize the claims. Industry stakeholders complain EFSA set the bar too high for many claims in its evaluation process, slated for completion by 2011 (1"The Tan Sheet" Jan. 11, 2010)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.